Short report

Cryotherapy in the management of paroxysmal trigeminal neuralgia

JOANNA M ZAKRZEWSKA

From the Department of Oral Medicine, University of London, Institute of Dental Surgery, London, UK

SUMMARY Cryotherapy for the relief of pain is widely used in many conditions. The results of 83 cryotherapy sessions in 29 patients with paroxysmal trigeminal neuralgia are reviewed over a five year period. Sixty three per cent of treated nerves, 41% of patients were pain free over one year and there was no permanent sensory loss.

Despite recent advances in treatment, trigeminal neuralgia remains an incapacitating condition which is difficult to treat successfully in every patient. At present it is standard practice to use carbamazepine as the first line of treatment, sometimes with the later addition of phenytoin. Even though many patients can be managed in the long term by carbamazepine, side effects are often unpleasant and quite a number of patients become intolerant. Taylor et al reported a 16 year follow up on 143 patients treated with carbamazepine and found it to be effective in 99 patients (69%), but 19 of those patients later became resistant to the drug and required a variety of surgical procedures.

In order to avoid major surgery, numerous peripheral techniques have been used. These have included peripheral neurectomy, alcohol, orphen injection, peripheral radiofrequency thermolysis, removal of jaw cysts, and peripheral streptomycin and lidocaine injections. None of the techniques appears to be curative and some may cause complications such as neuromas, anaesthesia dolorosa and neurological deficits.

The use of cryotherapy (cryoanalgesia) was first reported by Lloyd et al in 1976 with encouraging results. They treated 64 patients suffering from intractable pain, six of whom had "facial pain". Cryotherapy was used in a variety of facial pains, including post herpetic neuralgia, atypical facial pain and paroxysmal trigeminal neuralgia. They found that only the last named group really benefited from cryotherapy. Barnard et al in 1981 reported the use of cryotherapy in 24 patients with paroxysmal trigeminal neuralgia. Patients had a median relief period of 186 days but at the end of one year only 16% had full pain relief. Since 1978, cryotherapy for the relief of paroxysmal trigeminal neuralgia has been used at the Eastman Dental Hospital. Initially nitrous oxide was used as a refrigerant and then liquid nitrogen came to be used as the standard procedure. Since then 145 patients have been treated and 247 open nerve freezes performed on these patients.

Material and methods

Thirty nine patients were first treated with cryotherapy using liquid nitrogen over five years ago. Of these, six were lost to follow up, two died and two later underwent radiofrequency thermocoagulation of the Gasserian ganglion. Therefore 29 patients were considered who had been followed up for at least five years. The group included 16 females and 13 males with a mean age of 54 years (range 18–76 years). Twenty one of the patients had pain on the right side; 10 of these involved the right infra-orbital nerve. None in this series had pain in the ophthalmic division. Forty five per cent of the patients had suffered from paroxysmal trigeminal neuralgia for a period between 1 to 5 years. Strict diagnostic criteria were used. Pain was in the distribution of the trigeminal nerve and was of an electric shock, shooting or stabbing character. It was of short duration and showed periods of complete remission. Trigger zones could be elicited by innocuous stimuli such as light touch and vibration. No frank sensory deficit was found on gross neurological testing and radiological investigations, that is, lateral and postero-anterior skull radiographs and orthopantomograms of the jaws were nor-
The injection of local anaesthesia into the trigger zones abolished the pain. All patients had been treated with carbamazepine and although initially they showed a response, they subsequently became intolerant or unresponsive to it. Over 50% of the patients had suffered from the disease from 1 to 5 years. None had undergone neurosurgical procedures or had any neurolytic injections. Those with atypical clinical features were excluded, including those who had secondary trigeminal neuralgia. Repeat cryotherapy was done on those patients in whom pain returned.

Cryotherapy technique
Identification of the affected branch or branches was achieved prior to cryotherapy by injection of local anaesthesia with consequent abolition of pain. Patients were treated under intravenous sedation, together with local anaesthesia. The affected nerves were exposed using intra-oral techniques as far as possible. The exposed nerve was then frozen with the DFS 30 system (Spembly, Guildford), with a thermostatically controlled temperature of $-10^\circ\text{C}$. The cycle of a 2 minute freeze, followed by a 5 minute thaw was performed three times, taking care not to crush the nerve. If two branches were affected, both were treated simultaneously; most commonly these were the long buccal and mental nerves.

Results
Between them, the 29 patients had undergone 83 cryotherapy sessions in five years, the average being three. Seven patients had one cryotherapy session, but one patient had seven.

Table  Pain control period (PCP) for individual nerves

<table>
<thead>
<tr>
<th>Time in years</th>
<th>39 Infraorbital nerves</th>
<th>30 Mental nerves</th>
<th>23 Buccal nerves</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PCP</td>
<td>Pain free</td>
<td>PCP</td>
</tr>
<tr>
<td>0-1</td>
<td>28% (11)</td>
<td>5% (2)</td>
<td>37% (11)</td>
</tr>
<tr>
<td>1-2</td>
<td>31% (12)</td>
<td>3% (1)</td>
<td>23% (7)</td>
</tr>
<tr>
<td>2-3</td>
<td>8% (3)</td>
<td>8% (3)</td>
<td>7% (2)</td>
</tr>
<tr>
<td>3-4</td>
<td>0</td>
<td>3% (1)</td>
<td>20% (6)</td>
</tr>
<tr>
<td>4-5</td>
<td>0</td>
<td>3% (1)</td>
<td>0</td>
</tr>
<tr>
<td>5-6</td>
<td>0</td>
<td>13% (5)</td>
<td>0</td>
</tr>
</tbody>
</table>

The pain control period was said to have come to an end when the patient reported a recurrence of paroxysmal trigeminal neuralgia which necessitated the consistent use of carbamazepine of 200 mg tds or an equivalent dose of phenytoin for 2 weeks.

Eighty five per cent of patients gained immediate relief of their symptoms, and others required repeat cryotherapy or drug therapy. Long term results when assessed as the total pain control period were not as successful. Of the patients 56-6% had a pain control period of under one year, 25-3% for 1–2 years and 4-8% for 5–6 years (fig). However, this short period was often related to migration of the pain to other branches within the same division. This is borne out when one looks at the pain control period for individual nerves which is much longer than the total pain control period (table). I have assessed these for the infra orbital, the mental and the long buccal nerves. Too few freeees of the greater palatine, the posterior superior dental and lingual nerves were done to assess them statistically. In summary, 41% of patients had a pain control period of over a year, with 14-5% of patients having a pain control period of over 2 years. However, when looking at nerve pain control periods, it was found that 63% of nerves had a pain control period of over one year and 34% of nerves had a pain control period of over 2 years. The only complication was one infection post operatively, which cleared up after a course of antibiotics. All patients regained normal sensation of the face within 2 to 3 months.

Those patients who had repeat cryotherapy had equally good results on the second or any further subsequent times.

Discussion
No one surgical treatment is a 100% successful and even if the recurrence rate is low then the morbidity tends to be high.

Treatment by posterior fossa surgery involves either section (partial or total) of the trigeminal sensory root or microvascular decompression as described by Jannetta.\textsuperscript{13} Piatt and Wilkins\textsuperscript{14} feel both procedures are effective and excellent or good results were obtained in 77% (105) patients. Kolluri and
Cryotherapy in the management of paroxysmal trigeminal neuralgia

Heros\textsuperscript{15} compared several larger series of microvascular decompression and found an average recurrence rate of 22.5% in a total of 984 patients. Patients are left with no sensory disturbance but post operative complications included a 0.8% (8) mortality rate.\textsuperscript{15} Therefore, only medically fit patients should be submitted to these procedures. Hence percutaneous approaches to the Gasserian ganglion have become increasingly popular. Radiofrequency thermo-coagulation of the Gasserian ganglion as first described by Sweet and Wepsic\textsuperscript{16} gave encouraging results. Spincemaille \textit{et al}\textsuperscript{17} reported an 85% success rate in 45 patients and Mittal and Thomas\textsuperscript{18} reported 88% of 280 procedures pain free at one year. Unfortunately, the lesions are destructive and alter facial sensation. Glycerol chemoneurolysis\textsuperscript{19} appears to produce less numbness and dysesthesia with 90% excellent or good results.\textsuperscript{20} However, many patients are medically unfit or unwilling to undergo major surgery with its consequent mortality and morbidity and for this group peripheral techniques are the alternative. Results for all these methods are fairly similar. Alcohol injections have been reported to give pain relief for 11–16 months,\textsuperscript{2} 6–14.3 months\textsuperscript{4} but are not always successful, may result in facial palsy and are painful to perform. Peripheral neurectomies give slightly better results; 33.2 months pain relief\textsuperscript{2} or 26.5 months\textsuperscript{21} but the patient is left with a degree of facial numbness. Peripheral radiofrequency lesions of peripheral nerves\textsuperscript{5} have a recurrence rate of 68% at one year with an average effectiveness of 9.2 months but the lesions result in less sensory loss than those done at the level of the ganglion.

Cryotherapy with its average recurrence rate of 37% at one year compares favourably with these other techniques. In common with most of the other peripheral treatments cryotherapy is carried out under local anaesthesia and on an out-patient basis and so no patient needs to be excluded on medical grounds. Its major advantage lies in the fact that sensation returns to the area within 3 months. Nerve damage is, therefore, totally reversible as borne out not only experimentally,\textsuperscript{22,23} but also clinically.\textsuperscript{9–11,24} Return of sensation, no neuroma formation, neuritis or anaesthesia dolorosa, greatly improve the quality of life for these patients. Patients are willing and do undergo repeated cryotherapy with equally good results in order to avoid major surgery.

Cryotherapy has a role to play in the early management of trigeminal neuralgia, although it must be remembered that we are still a long way from achieving the perfect treatment which would result in pain relief with normal sensation and with no necessity for long term drug therapy or major surgery.

I am grateful to Dr FF Nally for his help in the preparation of this paper and for permission to report on his patients and to Miss J Hammett for her secretarial assistance.

\section*{References}

\textsuperscript{5} Gregg JM, Small EW. Surgical management of trigeminal pain with radiofrequency lesions of peripheral nerves. \textit{J Oral Maxillofac Surg} 1984;44:122–5.
\textsuperscript{18} Mittal B, Thomas DGT. Controlled thermo-coagulation in trigeminal neuralgia. \textit{J Neurol Neurosurg Psychiatry} 1986;49:932–6.
\textsuperscript{19} Hakanson S. Trigeminal neuralgia treated by the injection of glycerol into the trigeminal cistern. \textit{Neurosurgery} 1981;9:638–46.
Cryotherapy in the management of paroxysmal trigeminal neuralgia.

J M Zakrzewska

*J Neurol Neurosurg Psychiatry* 1987 50: 485-487
doi: 10.1136/jnnp.50.4.485

Updated information and services can be found at:
http://jnnp.bmj.com/content/50/4/485

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/